Compare CNS & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNS | LGND |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.7B |
| IPO Year | 2004 | 1997 |
| Metric | CNS | LGND |
|---|---|---|
| Price | $73.71 | $283.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $71.50 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 190.7K | 155.5K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ 2886.36 |
| EPS | ★ 1.77 | 1.63 |
| Revenue | ★ $427,536,000.00 | $141,102,000.00 |
| Revenue This Year | $4.71 | $1.25 |
| Revenue Next Year | $4.37 | $19.41 |
| P/E Ratio | ★ $41.14 | $174.66 |
| Revenue Growth | 4.07 | ★ 29.48 |
| 52 Week Low | $58.39 | $163.45 |
| 52 Week High | $86.56 | $326.63 |
| Indicator | CNS | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 33.40 | 47.26 |
| Support Level | $73.07 | $279.69 |
| Resistance Level | $74.01 | $294.00 |
| Average True Range (ATR) | 2.42 | 8.40 |
| MACD | -0.67 | -0.14 |
| Stochastic Oscillator | 24.22 | 53.29 |
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests primarily in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for nearly two-thirds of its $102.5 billion in managed assets at the end of July 2026. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.